
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4222880/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Defining radio-recurrent intra-prostatic target volumes using PSMA-targeted PET/CT and multi-parametric MRI. Clinical and Translational Radiation Oncology, 2022, 32, 41-47.	0.9	7
2	ASO Visual Abstract: The Effect of Preoperative Treatment on the Performance of Predictive Nomograms in Primary Retroperitoneal Sarcoma (RPS). Annals of Surgical Oncology, 2022, 29, 2315.	0.7	0
3	Effect of Preoperative Treatment on the Performance of Predictive Nomograms in Primary Retroperitoneal Sarcoma. Annals of Surgical Oncology, 2022, 29, 2304.	0.7	3
4	Radiological progression of extremity soft tissue sarcoma following pre-operative radiotherapy predicts for poor survival. British Journal of Radiology, 2022, 95, 20210936.	1.0	1
5	Dosimetric comparison of MR-guided adaptive IMRT versus 3DOF-VMAT for prostate stereotactic radiotherapy. Technical Innovations and Patient Support in Radiation Oncology, 2022, 21, 64-70.	0.6	Ο
6	The prognostic value of urinary cytology after trimodal therapy (TMT) for muscle-invasive bladder cancer. Urologic Oncology: Seminars and Original Investigations, 2022, , .	0.8	0
7	Case Report: MR-Guided Adaptive Radiotherapy, Some Room to Maneuver. Frontiers in Oncology, 2022, 12, 877452.	1.3	0
8	TNM Staging of Prostate Cancer: Challenges in Securing a Globally Applicable Classification. European Urology, 2022, 82, e52-e53.	0.9	2
9	Safety of Minimizing Intensity of Follow-up on Active Surveillance for Clinical Stage I Testicular Germ Cell Tumors. European Urology Open Science, 2022, 40, 46-53.	0.2	6
10	Utility of Serum miR-371a-3p in Predicting Relapse on Surveillance in Patients with Clinical Stage I Testicular Germ Cell Cancer. European Urology Oncology, 2021, 4, 483-491.	2.6	39
11	Utilization of Salvage and Systemic Therapies for Recurrent Prostate Cancer as a Result of 18F-DCFPyL PET/CT Restaging. Advances in Radiation Oncology, 2021, 6, 100553.	0.6	7
12	Coronavirus Disease 2019's (COVID-19's) Silver Lining—Through the Eyes of Radiation Oncology Fellows. Advances in Radiation Oncology, 2021, 6, 100527.	0.6	4
13	Long-term Surveillance of Patients with Complete Response Following Chemotherapy for Metastatic Nonseminomatous Germ Cell Tumor. European Urology Oncology, 2021, 4, 289-296.	2.6	13
14	Recent Advances in the Management of Penile Cancer: A Contemporary Review of the Literature. Oncology and Therapy, 2021, 9, 21-39.	1.0	20
15	Trimodal Therapy. , 2021, , 257-280.		0
16	Salvage lymph node dissection for prostate-specific membrane antigen (PSMA) positron emission tomography (PET)-identified oligometastatic disease. Canadian Urological Association Journal, 2021, 15, E545-E552.	0.3	3
17	Prostate or bone? Comparing the efficacy of image guidance surrogates for pelvis and prostate radiotherapy using accumulated delivered dose. Journal of Medical Imaging and Radiation Sciences, 2021, 52, 14-21.	0.2	1
18	Lack of Evidence Does Not Equal Lack of Benefit: Neoadjuvant Chemotherapy and Trimodality Therapy in Selected Patients with Muscle-Invasive Bladder Cancer. Current Oncology Reports, 2021, 23, 36.	1.8	2

#	Article	IF	CITATIONS
19	Characterization and management of NMIBC recurrences after TMT: a matched cohort analysis. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 835.e1-835.e7.	0.8	3
20	Radiation Therapy for Treatment of Soft Tissue Sarcoma in Adults: Executive Summary of an ASTRO Clinical Practice Guideline. Practical Radiation Oncology, 2021, 11, 339-351.	1.1	65
21	Curative-intent Metastasis-directed Therapies for Molecularly-defined Oligorecurrent Prostate Cancer: A Prospective Phase II Trial Testing the Oligometastasis Hypothesis. European Urology, 2021, 80, 374-382.	0.9	49
22	The Prognostic Value of Neutrophil-to-Lymphocyte Ratio in Metastatic Testicular Cancer. Current Oncology, 2021, 28, 107-114.	0.9	10
23	Trimodal therapy vs. radical cystectomy for muscle-invasive bladder cancer: A Markov microsimulation model. Canadian Urological Association Journal, 2021, 16, .	0.3	3
24	A Prospective Study of 18F-DCFPyL PSMA PET/CT Restaging in Recurrent Prostate Cancer following Primary External Beam Radiotherapy or Brachytherapy. International Journal of Radiation Oncology Biology Physics, 2020, 106, 546-555.	0.4	42
25	The role of chemotherapy and radiotherapy in localized extraskeletal osteosarcoma. European Journal of Cancer, 2020, 125, 130-141.	1.3	57
26	Simultaneous Vs Sequential Retroperitoneal, Thoracic and Cervical Resection of Post Chemotherapy Residual Masses in Patients With Metastatic Nonseminomatous Germ Cell Tumors of the Testis. Urology, 2020, 138, 69-76.	0.5	3
27	Salvage Radiotherapy Following Partial Gland Ablation for Prostate Cancer: Functional and Oncological Outcomes. European Urology Open Science, 2020, 21, 1-4.	0.2	1
28	Current topics in radiotherapy for genitourinary cancers: Consensus statements of the Genitourinary Radiation Oncologists of Canada. Canadian Urological Association Journal, 2020, 14, E588-E593.	0.3	4
29	Clinical dilemmas in local and regional testis cancer. Canadian Urological Association Journal, 2020, 15, E58-E64.	0.3	1
30	Preoperative radiotherapy plus surgery versus surgery alone for patients with primary retroperitoneal sarcoma (EORTC-62092: STRASS): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncology, The, 2020, 21, 1366-1377.	5.1	266
31	[¹⁸ F]DCFPyL PET-MRI/CT for unveiling a molecularly defined oligorecurrent prostate cancer state amenable for curative-intent ablative therapy: study protocol for a phase II trial. BMJ Open, 2020, 10, e035959.	0.8	8
32	A Canadian approach to the regionalization of testis cancer: A review. Canadian Urological Association Journal, 2020, 14, 346-351.	0.3	0
33	Use of combined androgen deprivation therapy with postoperative radiation treatment for prostate cancer: Impact of randomized trials on clinical practice. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 848.e1-848.e7.	0.8	3
34	Canadian experience of neoadjuvant chemotherapy on bladder recurrences in patients managed with trimodal therapy for muscle-invasive bladder cancer. Canadian Urological Association Journal, 2020, 14, 404-410.	0.3	3
35	Designing a Rational Follow-Up Schedule for Patients with Extremity Soft Tissue Sarcoma. Annals of Surgical Oncology, 2020, 27, 2033-2041.	0.7	14
36	Current Management of Localized Muscle-Invasive Bladder Cancer: AÂConsensus Guideline from the Genitourinary Medical Oncologists ofÂCanada. Bladder Cancer, 2020, 6, 363-392.	0.2	1

#	Article	IF	CITATIONS
37	Controversies in the management of clinical stage 1 testis cancer. Canadian Urological Association Journal, 2020, 14, E537-E542.	0.3	4
38	Trimodality Therapy for Muscle-Invasive Bladder Cancer: Recent Advances and Unanswered Questions. Current Oncology Reports, 2020, 22, 14.	1.8	16
39	Tumor-targeted dose escalation for localized prostate cancer using MR-guided HDR brachytherapy (HDR) or integrated VMAT (IB-VMAT) boost: Dosimetry, toxicity and health related quality of life. Radiotherapy and Oncology, 2020, 149, 240-245.	0.3	10
40	Dose to the bladder neck in MRI-guided high-dose-rate prostate brachytherapy: Impact on acute urinary toxicity and health-related quality of life. Brachytherapy, 2019, 18, 477-483.	0.2	7
41	Treatment of Relapse of Clinical Stage I Nonseminomatous Germ Cell Tumors on Surveillance. Journal of Clinical Oncology, 2019, 37, 1919-1926.	0.8	47
42	Extraprostatic Extension in Core Biopsies Epitomizes High-risk but Locally Treatable Prostate Cancer. European Urology Oncology, 2019, 2, 88-96.	2.6	7
43	Low dose radiotherapy is associated with local complications but not disease control in sacral chordoma. Journal of Surgical Oncology, 2019, 119, 856-863.	0.8	37
44	Impact of high dose volumetric CT on PTV margin reduction in VMAT prostate radiotherapy. Physics in Medicine and Biology, 2019, 64, 065017.	1.6	2
45	Continuing towards optimization of bladder cancer care in Canada: Summary of the 3rd BCC-CUA-CUOG bladder cancer quality of care consensus meeting. Canadian Urological Association Journal, 2019, 14, E115-E125.	0.3	3
46	Detection of Relapse by Low-dose Computed Tomography During Surveillance in Stage I Testicular Germ Cell Tumours. European Urology Oncology, 2019, 2, 437-442.	2.6	11
47	Radiotherapy for retroperitoneal liposarcoma: A report from the Transatlantic Retroperitoneal Sarcoma Working Group. Cancer, 2019, 125, 1290-1300.	2.0	71
48	Changes in apparent diffusion coefficient radiomics features during dose-painted radiotherapy and high dose rate brachytherapy for prostate cancer. Physics and Imaging in Radiation Oncology, 2019, 9, 1-6.	1.2	14
49	Quantification of interobserver variability in image registration using cone beam CT for partial bladder radiotherapy—a comparison between lipiodol and bladder wall surface. British Journal of Radiology, 2019, 92, 20180413.	1.0	3
50	Comparison of 3 image-guided adaptive strategies for bladder locoregional radiotherapy. Medical Dosimetry, 2019, 44, 111-116.	0.4	14
51	International Multicenter Validation of an Intermediate Risk Subclassification of Prostate Cancer Managed with Radical Treatment without Hormone Therapy. Journal of Urology, 2019, 201, 284-291.	0.2	18
52	Case series illustrating the synergistic use of hydrogel spacer and MR-guidance to increase the radiotherapeutic index for localized prostate cancer. Technical Innovations and Patient Support in Radiation Oncology, 2019, 11, 22-25.	0.6	2
53	STRASS (EORTC 62092): A phase III randomized study of preoperative radiotherapy plus surgery versus surgery alone for patients with retroperitoneal sarcoma Journal of Clinical Oncology, 2019, 37, 11001-11001.	0.8	64
54	Serum miRNA Predicts Viable Disease after Chemotherapy in Patients with Testicular Nonseminoma Germ Cell Tumor. Journal of Urology, 2018, 200, 126-135.	0.2	107

#	Article	IF	CITATIONS
55	Evidence-based region of interest matching guidelines for sarcoma volumetric image-guided radiation therapy. Technical Innovations and Patient Support in Radiation Oncology, 2018, 5, 3-8.	0.6	2
56	A New Model to Predict Benign Histology in Residual Retroperitoneal Masses After Chemotherapy in Nonseminoma. European Urology Focus, 2018, 4, 995-1001.	1.6	26
57	Curative Radiation Therapy at Time of Progression Under Active Surveillance Compared With Up-front Radical Radiation Therapy for Prostate Cancer. International Journal of Radiation Oncology Biology Physics, 2018, 100, 702-709.	0.4	1
58	Testicular seminoma: Scattered radiation dose to the contralateral testis in the modern era. Practical Radiation Oncology, 2018, 8, e57-e62.	1.1	3
59	The Bladder Utility Symptom Scale: A Novel Patient Reported Outcome Instrument for Bladder Cancer. Journal of Urology, 2018, 200, 283-291.	0.2	22
60	Impact of Granulocyte-colony Stimulating Factor on Bleomycin-induced Pneumonitis in Chemotherapy-treated Germ Cell Tumors. Clinical Genitourinary Cancer, 2018, 16, e193-e199.	0.9	13
61	Radiation therapy in retroperitoneal sarcoma management. Journal of Surgical Oncology, 2018, 117, 93-98.	0.8	25
62	Dosimetric impact of intrafraction changes in MR-guided high-dose-rate (HDR) brachytherapy for prostate cancer. Brachytherapy, 2018, 17, 59-67.	0.2	6
63	Applying Radiomics to Predict Pathology of Postchemotherapy Retroperitoneal Nodal Masses in Germ Cell Tumors. JCO Clinical Cancer Informatics, 2018, 2, 1-12.	1.0	21
64	Reply to A. Levy et al. Journal of Clinical Oncology, 2018, 36, 2358-2359.	0.8	0
65	Analysis of Margin Classification Systems for Assessing the Risk of Local Recurrence After Soft Tissue Sarcoma Resection. Journal of Clinical Oncology, 2018, 36, 704-709.	0.8	155
66	Canadian Urological Association guideline: Muscle-invasive bladder cancer. Canadian Urological Association Journal, 2018, 13, 230-238.	0.3	51
67	Efficient and Effective Personalization of PTV Margins During Radiation Therapy for Bladder Cancer. Journal of Medical Imaging and Radiation Sciences, 2018, 49, 420-427.	0.2	3
68	Improving patient journey and quality of care: Summary from the second Bladder Cancer Canada-Canadian Urological Association- Canadian Urologic Oncology Group (BCC-CUA-CUOG) bladder cancer quality of care consensus meeting. Canadian Urological Association Journal, 2018, 12, E281-97.	0.3	9
69	Gene expression signatures prognostic for relapse in stage I testicular germ cell tumours. BJU International, 2018, 122, 814-822.	1.3	8
70	Evaluation of resource burden for bladder adaptive strategies: A timing study. Journal of Medical Imaging and Radiation Oncology, 2018, 62, 861-865.	0.9	4
71	Magnetic Resonance Imaging-guided Brachytherapy Re-irradiation for Isolated Local Recurrence of Soft Tissue Sarcoma. Cureus, 2018, 10, e2457.	0.2	4
72	Quality indicators in the management of bladder cancer: A modified Delphi study. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 328-334.	0.8	29

#	Article	IF	CITATIONS
73	MR elastography to measure the effects of cancer and pathology fixation on prostate biomechanics, and comparison with <i>T</i> ₁ , <i>T</i> ₂ and ADC. Physics in Medicine and Biology, 2017, 62, 1126-1148.	1.6	8
74	The value of adaptive preoperative radiotherapy in management of soft tissue sarcoma. Radiotherapy and Oncology, 2017, 122, 458-463.	0.3	17
75	Regional Therapy Might Have a Role. International Journal of Radiation Oncology Biology Physics, 2017, 99, 511.	0.4	0
76	An Analysis of Tumor- and Surgery-Related Factors that Contribute to Inadvertent Positive Margins Following Soft Tissue Sarcoma Resection. Annals of Surgical Oncology, 2017, 24, 2137-2144.	0.7	21
77	Improved outcomes with dose escalation in localized prostate cancer treated with precision image-guided radiotherapy. Radiotherapy and Oncology, 2017, 123, 459-465.	0.3	18
78	Survival outcomes for cutaneous angiosarcoma of the scalp versus face. Head and Neck, 2017, 39, 1205-1211.	0.9	42
79	Dosimetric feasibility of ablative dose escalated focal monotherapy with MRI-guided high-dose-rate (HDR) brachytherapy for prostate cancer. Radiotherapy and Oncology, 2017, 122, 103-108.	0.3	8
80	Evaluation of high dose volumetric CT to reduce inter-observer delineation variability and PTV margins for prostate cancer radiotherapy. Radiotherapy and Oncology, 2017, 125, 118-123.	0.3	16
81	Stereotactic ablative radiotherapy with targeted MRI-defined gross tumor dose escalation for prostate cancer: dosimetric feasibility and interfraction robustness. Journal of Radiation Oncology, 2017, 6, 397-404.	0.7	0
82	Outcome following radiotherapy for head and neck basal cell carcinoma with â€~aggressive' features. Oral Oncology, 2017, 72, 157-164.	0.8	15
83	The effect of bowel preparation regime on interfraction rectal filling variation during image guided radiotherapy for prostate cancer. Radiation Oncology, 2017, 12, 50.	1.2	7
84	Conditional Risk of Relapse in Surveillance for Clinical Stage I Testicular Cancer. European Urology, 2017, 71, 120-127.	0.9	54
85	Long-term outcomes of a phase II trial of moderate hypofractionated image-guided intensity modulated radiotherapy (IG-IMRT) for localized prostate cancer. Radiotherapy and Oncology, 2017, 122, 93-98.	0.3	23
86	Tumour-Targeted Treatment Intensification for Prostate Cancer Using Magnetic Resonance Imaging Guidance. Journal of Medical Imaging and Radiation Sciences, 2017, 48, 336-342.	0.2	1
87	Recommendations for followup of stage I and II seminoma: The Princess Margaret Cancer Centre approach. Canadian Urological Association Journal, 2017, 12, 59-66.	0.3	12
88	Use of hydrogel spacer for improved rectal dose-sparing in patients undergoing radical radiotherapy for localized prostate cancer: First Canadian experience. Canadian Urological Association Journal, 2017, 11, 373-5.	0.3	1
89	Retroperitoneal hematoma following radical orchiectomy: Two cases. Canadian Urological Association Journal, 2017, 11, 35.	0.3	3
90	Propensity Score Analysis of Radical Cystectomy Versus Bladder-Sparing Trimodal Therapy in the Setting of a Multidisciplinary Bladder Cancer Clinic. Journal of Clinical Oncology, 2017, 35, 2299-2305.	0.8	241

#	Article	IF	CITATIONS
91	Randomized Trial of a Hypofractionated Radiation Regimen for the Treatment of Localized Prostate Cancer. Journal of Clinical Oncology, 2017, 35, 1884-1890.	0.8	521
92	Long-Term Quality of Life of Retroperitoneal Sarcoma Patients Treated with Pre-Operative Radiotherapy and Surgery. Cureus, 2017, 9, e1764.	0.2	10
93	The association between institution at orchiectomy and outcomes on active surveillance for clinical stage I germ cell tumours. Canadian Urological Association Journal, 2016, 10, 204.	0.3	10
94	Technical Note: Method to correlate whole-specimen histopathology of radical prostatectomy with diagnostic MR imaging. Medical Physics, 2016, 43, 1065-1072.	1.6	10
95	Planned versus â€~delivered' bladder dose reconstructed using solid and hollow organ models during prostate cancer IMRT. Radiotherapy and Oncology, 2016, 119, 417-422.	0.3	8
96	Health-related quality of life following treatment for extremity soft tissue sarcoma. Journal of Surgical Oncology, 2016, 114, 821-827.	0.8	16
97	PMH 9907: Longâ€term outcomes of a randomized phase 3 study of shortâ€term bicalutamide hormone therapy and doseâ€escalated externalâ€beam radiation therapy for localized prostate cancer. Cancer, 2016, 122, 2595-2603.	2.0	14
98	Automated Delineation of the Normal Urinary Bladder on Planning CT andÂCone Beam CT. Journal of Medical Imaging and Radiation Sciences, 2016, 47, 21-29.	0.2	4
99	Assessment of intravascular granulomas in testicular seminomas and their association with tumour relapse and dissemination. Journal of Clinical Pathology, 2016, 69, 47-52.	1.0	4
100	Lessons learned using an MRI-only workflow during high-dose-rate brachytherapy for prostate cancer. Brachytherapy, 2016, 15, 147-155.	0.2	28
101	Impact of image registration surrogates on the planning target volume geometry for bladder radiation therapy. Practical Radiation Oncology, 2016, 6, e187-e194.	1.1	5
102	Brain Metastases in Patients With Germ Cell Tumors: Prognostic Factors and Treatment Options—An Analysis From the Global Germ Cell Cancer Group. Journal of Clinical Oncology, 2016, 34, 345-351.	0.8	69
103	The initiation of a multidisciplinary bladder cancer clinic and the uptake of neoadjuvant chemotherapy: A time-series analysis. Canadian Urological Association Journal, 2016, 10, 25.	0.3	17
104	Enumerating pelvic recurrence following radical cystectomy for bladder cancer: A Canadian multi-institutional study. Canadian Urological Association Journal, 2016, 10, 90.	0.3	6
105	Recommendations for the improvement of bladder cancer quality of care in Canada: A consensus document reviewed and endorsed by Bladder Cancer Canada (BCC), Canadian Urologic Oncology Group (CUOG), and Canadian Urological Association (CUA), December 2015. Canadian Urological Association Association Iournal. 2016. 10. 46.	0.3	55
106	Testicular cancer: germ cell tumours. Clinical Evidence, 2016, 2016, .	0.2	3
107	Evaluation of a prognostic model for risk of relapse in stage I seminoma surveillance. Cancer Medicine, 2015, 4, 155-160.	1.3	129
108	MR-guided Prostate Biopsy for Planning of Focal Salvage after Radiation Therapy. Radiology, 2015, 274, 181-191.	3.6	40

#	Article	IF	CITATIONS
109	Readout-segmented echo-planar diffusion-weighted imaging improves geometric performance for image-guided radiation therapy of pelvic tumors. Radiotherapy and Oncology, 2015, 117, 525-531.	0.3	23
110	Lymph Node Yield in Primary Retroperitoneal Lymph Node Dissection for Nonseminoma Germ Cell Tumors. Journal of Urology, 2015, 194, 386-391.	0.2	23
111	Phase 2 trial of guideline-based postoperative image guided intensity modulated radiation therapy for prostate cancer: Toxicity, biochemical, and patient-reported health-related quality-of-life outcomes. Practical Radiation Oncology, 2015, 5, e473-e482.	1.1	24
112	Delineating the inner bladder surface using uniform contractions from the outer surface under variable bladder filling conditions. British Journal of Radiology, 2015, 88, 20140818.	1.0	2
113	Patterns of Relapse in Patients With Clinical Stage I Testicular Cancer Managed With Active Surveillance. Journal of Clinical Oncology, 2015, 33, 51-57.	0.8	268
114	The effect of the setting of a positive surgical margin in soft tissue sarcoma. Cancer, 2014, 120, 2866-2875.	2.0	139
115	Spatial and volumetric changes of retroperitoneal sarcomas during pre-operative radiotherapy. Radiotherapy and Oncology, 2014, 112, 308-313.	0.3	19
116	Deriving patient-specific planning target volume for partial bladder image guided radiation therapy. Practical Radiation Oncology, 2014, 4, 323-329.	1.1	7
117	Salvage MRI-Guided and Tumor-Targeted HDR Prostate Brachytherapy after External Beam Radiotherapy. Brachytherapy, 2014, 13, S38-S39.	0.2	2
118	Reply to monitoring of seminoma patients with serum markers. Cancer, 2013, 119, 2511-2512.	2.0	0
119	Prostate radiotherapy clinical trial quality assurance: How real should real time review be? (A) Tj ETQq1 1 0.7843	I4 ₀ gBT /O	verlock 10 Th
120	Contemporary Management of Stage I and II Seminoma. Current Urology Reports, 2013, 14, 525-533.	1.0	13
121	Changes in apparent diffusion coefficient and T ₂ relaxation during radiotherapy for prostate cancer. Journal of Magnetic Resonance Imaging, 2013, 37, 909-916.	1.9	74
122	Treatment burden in stage <scp>I</scp> seminoma: a comparison of surveillance and adjuvant radiation therapy. BJU International, 2013, 112, 1088-1095.	1.3	40
123	Canadian consensus guidelines for the management of testicular germ cell cancer. Canadian Urological Association Journal, 2013, 4, 19.	0.3	119
124	Treatment-related toxicity and symptom-related bother followingpostoperative radiotherapy for prostate cancer. Canadian Urological Association Journal, 2013, 4, 105.	0.3	13
125	Tumor Hypoxia Predicts Biochemical Failure following Radiotherapy for Clinically Localized Prostate Cancer. Clinical Cancer Research, 2012, 18, 2108-2114.	3.2	233
126	Testicular cancer survivors' supportive care needs and use of online support: a cross-sectional survey. Supportive Care in Cancer, 2012, 20, 2737-2746.	1.0	65

#	Article	IF	CITATIONS
127	Pathological Predictors for Site of Local Recurrence After Radiotherapy for Prostate Cancer. International Journal of Radiation Oncology Biology Physics, 2012, 82, e441-e448.	0.4	52
128	Inverse Relationship Between Biochemical Outcome and Acute Toxicity After Image-Guided Radiotherapy for Prostate Cancer. International Journal of Radiation Oncology Biology Physics, 2012, 83, 608-616.	0.4	10
129	In regard to RTOG Sarcoma Radiation Oncologists Reach Consensus on Gross Tumor Volume and Clinical Target Volume on Computed Tomographic Images for Preoperative Radiotherapy of Primary Soft Tissue Sarcoma of Extremity in Radiation Therapy Oncology Group Studies: In regard to Wang etÂal (Int J Radiat Oncol Biol Phys 2011;81:e525–e528). International Journal of Radiation Oncology Biology	0.4	5
130	Physics, 2012, 83, 483. Radiation Therapy for Infiltrative Giant Cell Tumor of the Tendon Sheath. Journal of Hand Surgery, 2012, 37, 775-782.	0.7	11
131	The clinical and functional outcome for patients with radiationâ€induced soft tissue sarcoma. Cancer, 2012, 118, 2682-2692.	2.0	67
132	Utility of serum tumor markers during surveillance for stage I seminoma. Cancer, 2012, 118, 5245-5250.	2.0	33
133	Local recurrence of localized soft tissue sarcoma. Cancer, 2012, 118, 5867-5877.	2.0	100
134	Soft Tissue Sarcoma. , 2012, , 1355-1391.		1
135	Patient-specific PTV margins in radiotherapy for bladder cancer – A feasibility study using cone beam CT. Radiotherapy and Oncology, 2011, 99, 131-136.	0.3	31
136	The effect of delineation method and observer variability on bladder dose-volume histograms for prostate intensity modulated radiotherapy. Radiotherapy and Oncology, 2011, 101, 479-485.	0.3	23
137	Role of Principal Component Analysis in Predicting Toxicity in Prostate Cancer Patients Treated With Hypofractionated Intensity-Modulated Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2011, 81, e415-e421.	0.4	25
138	The Effect of Registration Surrogate and Patient Factors on the Interobserver Variability of Electronic Portal Image Guidance During Prostate Radiotherapy. Medical Dosimetry, 2011, 36, 337-343.	0.4	6
139	Prostate T ₁ quantification using a magnetizationâ€prepared spiral technique. Journal of Magnetic Resonance Imaging, 2011, 33, 474-481.	1.9	6
140	Soft tissue sarcoma presenting with metastatic disease. Cancer, 2011, 117, 372-379.	2.0	64
141	Highâ€risk extracranial chondrosarcoma. Cancer, 2011, 117, 2513-2519.	2.0	42
142	Stage I Seminoma: Adjuvant Treatment is Effective but is it Necessary?. Journal of the National Cancer Institute, 2011, 103, 194-196.	3.0	38
143	Adverse Effect of Older Age on the Recurrence of Soft Tissue Sarcoma of the Extremities and Trunk. Journal of Clinical Oncology, 2011, 29, 4029-4035.	0.8	47
144	Axial Skeletal Location Predicts Poor Outcome in Ewing's Sarcoma: A Single Institution Experience. Sarcoma, 2011, 2011, 1-5.	0.7	9

#	Article	IF	CITATIONS
145	Testicular cancer: seminoma. Clinical Evidence, 2011, 2011, .	0.2	5
146	Comparison of low dose with standard dose abdominal/pelvic multidetector CT in patients with stage 1 testicular cancer under surveillance. European Radiology, 2010, 20, 1624-1630.	2.3	41
147	No Role for Routine Chest Radiography in Stage I Seminoma Surveillance. European Urology, 2010, 57, 474-479.	0.9	33
148	Primary Tracheal Ewing's Sarcoma. Annals of Thoracic Surgery, 2010, 90, 1349-1352.	0.7	11
149	Clinical prostate T ₂ quantification using magnetizationâ€prepared spiral imaging. Magnetic Resonance in Medicine, 2010, 64, 1155-1161.	1.9	12
150	Clinical Application of High-Dose, Image-Guided Intensity-Modulated Radiotherapy in High-Risk Prostate Cancer. International Journal of Radiation Oncology Biology Physics, 2010, 77, 477-483.	0.4	29
151	The relationship between external beam radiotherapy dose and chronic urinary dysfunction – A methodological critique. Radiotherapy and Oncology, 2010, 97, 40-47.	0.3	49
152	Image guided dose escalated prostate radiotherapy: still room to improve. Radiation Oncology, 2009, 4, 50.	1.2	57
153	A Device and Procedure for Immobilization of Patients Receiving Limb-Preserving Radiotherapy for Soft Tissue Sarcoma. Medical Dosimetry, 2009, 34, 243-249.	0.4	23
154	Prostate delineation using CT and MRI for radiotherapy patients with bilateral hip prostheses. Radiotherapy and Oncology, 2009, 90, 325-330.	0.3	30
155	Inter-professional variability in the assignment and recording of acute toxicity grade using the RTOG system during prostate radiotherapy. Radiotherapy and Oncology, 2009, 90, 395-399.	0.3	17
156	Dynamic Contrast-Enhanced Magnetic Resonance Imaging forÂLocalization of Recurrent Prostate Cancer After ExternalÂBeam Radiotherapy. International Journal of Radiation Oncology Biology Physics, 2008, 70, 425-430.	0.4	234
157	A randomized comparison of interfraction and intrafraction prostate motion with and without abdominal compression. Radiotherapy and Oncology, 2008, 88, 88-94.	0.3	25
158	Androgen Withdrawal in Patients Reduces Prostate Cancer Hypoxia: Implications for Disease Progression and Radiation Response. Cancer Research, 2007, 67, 6022-6025.	0.4	109
159	Long-term outcome of radiation-based conservation therapy for invasive bladder cancer. Urologic Oncology: Seminars and Original Investigations, 2007, 25, 303-309.	0.8	98
160	Evidence-based guidelines for following stage 1 seminoma. Cancer, 2007, 109, 2248-2256.	2.0	73
161	Patient-Assessed Late Toxicity Rates and Principal Component Analysis After Image-Guided Radiation Therapy for Prostate Cancer. International Journal of Radiation Oncology Biology Physics, 2007, 68, 690-698.	0.4	53
162	Phase II Trial of Hypofractionated Image-Guided Intensity-Modulated Radiotherapy for Localized Prostate Adenocarcinoma. International Journal of Radiation Oncology Biology Physics, 2007, 69, 1084-1089.	0.4	139

#	Article	IF	CITATIONS
163	Surveillance in stage I testicular seminoma. Urologic Oncology: Seminars and Original Investigations, 2006, 24, 75-79.	0.8	21
164	Treatment Options, Prognostic Factors and Selection of Treatment in Stage I Seminoma. Oncology Research and Treatment, 2006, 29, 592-598.	0.8	9
165	A phase II study of localized prostate cancer treated to 75.6Gy with 3D conformal radiotherapy. Radiotherapy and Oncology, 2005, 76, 11-17.	0.3	47
166	Spermatocytic Seminoma: A Review. European Urology, 2004, 45, 495-498.	0.9	66
167	Stage II Testicular Seminoma: Patterns of Recurrence and Outcome of Treatment. European Urology, 2004, 45, 754-760.	0.9	115